These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

757 related items for PubMed ID: 31511065

  • 1. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S, Leiter A, Galsky M, Gallagher EJ.
    J Immunother Cancer; 2019 Sep 12; 7(1):248. PubMed ID: 31511065
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC, Liu Y, Xie C, Cao BS.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr 18; 54(2):369-375. PubMed ID: 35435206
    [Abstract] [Full Text] [Related]

  • 4. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T.
    Medicine (Baltimore); 2023 Dec 22; 102(51):e36664. PubMed ID: 38134115
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists.
    Druce I, Tawagi K, Shaw JLV, Ibrahim A, Lochnan H, Ong M.
    Curr Oncol; 2022 Jul 02; 29(7):4665-4677. PubMed ID: 35877230
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A, Bhat R, Cousins J.
    Curr Probl Cancer; 2021 Feb 02; 45(1):100644. PubMed ID: 32888700
    [Abstract] [Full Text] [Related]

  • 11. Nivolumab induced hypophysitis in an advanced RCC patient.
    Korkmaz Yilmaz M, Gulturk I, Tacar SY, Yilmaz M.
    J Oncol Pharm Pract; 2022 Apr 02; 28(3):759-762. PubMed ID: 35006033
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
    Rai M, Go M.
    Cureus; 2020 Apr 10; 12(4):e7625. PubMed ID: 32399358
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
    Mishima Y, Fukaishi T, Inase N, Isogai S.
    Intern Med; 2019 Mar 01; 58(5):693-697. PubMed ID: 30449786
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
    Bando H, Yamamoto M, Urai S, Motomura Y, Sasaki Y, Ohmachi Y, Kobatake M, Tsujimoto Y, Oi-Yo Y, Suzuki M, Yamamoto N, Takahashi M, Fukuoka H, Iguchi G, Ogawa W.
    J Immunother Cancer; 2024 Feb 28; 12(2):. PubMed ID: 38418395
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.